{
    "info": {
        "nct_id": "NCT04561362",
        "official_title": "Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies",
        "inclusion_criteria": "Key Inclusion Criteria\n\n* Life expectancy ≥12 weeks.\n* Patients must have measurable disease per RECIST 1.1.\n* Part A-1 cohorts:\n* Must have exhausted all standard treatment options, including appropriate targeted therapies; or patients for which no standard therapy is considered appropriate\n* Patients with advanced, histologically confirmed urothelial (transitional cell) carcinoma that recurred after or has been refractory to prior therapy (fresh tumor biopsy or an archived sample must be submitted); or\n* Patients with advanced, histologically confirmed pancreatic, breast, non-small-cell lung cancer (NSCLC), gastric, esophageal, head and neck, or ovarian tumors that recurred after or has been refractory to prior therapy (fresh tumor biopsy or an archived sample testing for Nectin-4 expression).\n* Part A-2:\n* Must have exhausted all standard treatment options, including appropriate targeted therapies; or patients for which no standard therapy is considered appropriate\n* Patients with advanced, histologically confirmed urothelial (transitional cell) carcinoma that have progressed following prior therapy\n* Cohort B-1: Histologically documented urothelial carcinoma, previously treated with enfortumab vedotin (EV). Patients with resectable, locally advanced urothelial carcinoma are ineligible. Must have had progression or recurrence of urothelial cancer during or following receipt of most recent therapy.\n* Cohort B-2 and B-3: Histologically documented urothelial carcinoma, not previously treated with enfortumab vedotin (EV). Patients with resectable, locally advanced urothelial carcinoma are ineligible. Must have had progression or recurrence of urothelial cancer during or following receipt of most recent therapy.\n* Cohort B-4: Patients with histologically confirmed non-mucinous epithelial ovarian, fallopian tube, or primary peritoneal cancer that is Stage III or IV according to the International Federation of Gynecology and Obstetrics (FIGO) or tumor, node and metastasis staging criteria that have progressed following prior therapy.\n* Cohort B-5: Patients with triple-negative breast cancer confirmed negative for estrogen receptor (ER) and progesterone receptor (PR) and negative for human epidermal growth factor receptor 2 (HER2) (i.e., triple-negative) that have progressed following prior therapy.\n* Cohort B-6: Patients with histologically confirmed non-small cell lung cancer (NSCLC) with no actionable mutations, such as Epidermal Growth Factor Receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion oncogene, or ROS1 that have progressed following prior therapy.\n* Cohort B-7: Locally advanced or metastatic, histologically confirmed urothelial (transitional cell) carcinoma, ineligible for cisplatin, no prior systemic anticancer treatment for advanced urothelial carcinoma.\n* Cohort B-8: Locally advanced (unresectable) or metastatic, histologically confirmed breast cancer, either TNBC or hormone receptor (HR) positive and HER-2 negative according to ASCO/CAP guidelines and up to 3 prior lines of therapy for advanced (unresectable) or metastatic disease.\n* Cohort B-9: Histologically confirmed advanced/metastatic squamous or non-squamous NSCLC, negative for oncogenic driver mutations (EGFR, KRAS, ALK, BRAF, MET, ERRB2).\n* Cohort C renal insufficiency cohort: Patients with histologically documented urothelial carcinoma, ovarian, triple negative breast, or non-small cell lung cancer that have been previously treated with a locally approved therapy.\n* Part D supplementary PK: Patients must have histologically confirmed urothelial (transitional cell) carcinoma (patients with squamous differentiation or mixed cell types are eligible); ovarian; triple-negative breast; or non-small cell lung cancer that have been previously treated with a locally approved therapy.\n\nKey Exclusion Criteria (all patients):\n\n* Clinically relevant troponin elevation\n* Uncontrolled diabetes\n* Known active or untreated CNS and/or carcinomatous meningitis\n* Grade ≥2 peripheral neuropathy\n* Active keratitis or corneal ulcerations\n* Patients with uncontrolled hypertension\n* History of another malignancy within 3 years before first dose of BT8009 or residual disease from a previously diagnosed malignancy (with some exceptions).\n* Active systemic infection requiring therapy, or fever within the last 14 days prior to first dose of BT8009.\n* Prior Stevens-Johnson syndrome/toxic epidermal necrolysis on any MMAE-conjugated drug\n* Parts A-2 and B-7 Pembrolizumab Combination Cohorts:\n* Prior organ transplant (including allogeneic)\n* Diagnosis of clinically relevant immunodeficiency\n* History of interstitial lung disease\n* Parts B-2 and B-3: Prior treatment with enfortumab vedotin Other protocol-defined Inclusion/Exclusion criteria may apply\n* Parts B-8 and B-9: Prior treatment with an ADC containing an MMAE (vedotin) payload.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Clinically relevant troponin elevation",
            "criterions": [
                {
                    "exact_snippets": "Clinically relevant troponin elevation",
                    "criterion": "troponin",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": "clinically relevant elevation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with advanced, histologically confirmed urothelial (transitional cell) carcinoma that have progressed following prior therapy",
            "criterions": [
                {
                    "exact_snippets": "advanced, histologically confirmed urothelial (transitional cell) carcinoma",
                    "criterion": "urothelial (transitional cell) carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        }
                    ]
                },
                {
                    "exact_snippets": "have progressed following prior therapy",
                    "criterion": "disease progression after prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression after prior therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior organ transplant (including allogeneic)",
            "criterions": [
                {
                    "exact_snippets": "Prior organ transplant (including allogeneic)",
                    "criterion": "organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must have exhausted all standard treatment options, including appropriate targeted therapies; or patients for which no standard therapy is considered appropriate",
            "criterions": [
                {
                    "exact_snippets": "Must have exhausted all standard treatment options, including appropriate targeted therapies",
                    "criterion": "standard treatment options",
                    "requirements": [
                        {
                            "requirement_type": "exhaustion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients for which no standard therapy is considered appropriate",
                    "criterion": "standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "appropriateness",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cohort C renal insufficiency cohort: Patients with histologically documented urothelial carcinoma, ovarian, triple negative breast, or non-small cell lung cancer that have been previously treated with a locally approved therapy.",
            "criterions": [
                {
                    "exact_snippets": "histologically documented urothelial carcinoma, ovarian, triple negative breast, or non-small cell lung cancer",
                    "criterion": "cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "urothelial carcinoma",
                                "ovarian cancer",
                                "triple negative breast cancer",
                                "non-small cell lung cancer"
                            ]
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically documented"
                        }
                    ]
                },
                {
                    "exact_snippets": "have been previously treated with a locally approved therapy",
                    "criterion": "prior treatment with locally approved therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy approval status",
                            "expected_value": "locally approved"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior Stevens-Johnson syndrome/toxic epidermal necrolysis on any MMAE-conjugated drug",
            "criterions": [
                {
                    "exact_snippets": "Prior Stevens-Johnson syndrome/toxic epidermal necrolysis on any MMAE-conjugated drug",
                    "criterion": "history of Stevens-Johnson syndrome or toxic epidermal necrolysis on MMAE-conjugated drug",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "drug association",
                            "expected_value": "MMAE-conjugated drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Parts A-2 and B-7 Pembrolizumab Combination Cohorts:",
            "criterions": [
                {
                    "exact_snippets": "Parts A-2 and B-7 Pembrolizumab Combination Cohorts",
                    "criterion": "trial cohort assignment",
                    "requirements": [
                        {
                            "requirement_type": "cohort",
                            "expected_value": [
                                "Parts A-2",
                                "B-7"
                            ]
                        },
                        {
                            "requirement_type": "treatment",
                            "expected_value": "Pembrolizumab Combination"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cohort B-6: Patients with histologically confirmed non-small cell lung cancer (NSCLC) with no actionable mutations, such as Epidermal Growth Factor Receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion oncogene, or ROS1 that have progressed following prior therapy.",
            "criterions": [
                {
                    "exact_snippets": "histologically confirmed non-small cell lung cancer (NSCLC)",
                    "criterion": "non-small cell lung cancer (NSCLC)",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                },
                {
                    "exact_snippets": "no actionable mutations, such as Epidermal Growth Factor Receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion oncogene, or ROS1",
                    "criterion": "actionable mutations (EGFR, ALK, ROS1)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "have progressed following prior therapy",
                    "criterion": "disease progression after prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Parts B-2 and B-3: Prior treatment with enfortumab vedotin Other protocol-defined Inclusion/Exclusion criteria may apply",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with enfortumab vedotin",
                    "criterion": "prior treatment with enfortumab vedotin",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled diabetes",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled diabetes",
                    "criterion": "diabetes",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cohort B-7: Locally advanced or metastatic, histologically confirmed urothelial (transitional cell) carcinoma, ineligible for cisplatin, no prior systemic anticancer treatment for advanced urothelial carcinoma.",
            "criterions": [
                {
                    "exact_snippets": "Locally advanced or metastatic",
                    "criterion": "urothelial carcinoma stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "histologically confirmed urothelial (transitional cell) carcinoma",
                    "criterion": "urothelial (transitional cell) carcinoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histological"
                        }
                    ]
                },
                {
                    "exact_snippets": "ineligible for cisplatin",
                    "criterion": "cisplatin eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "no prior systemic anticancer treatment for advanced urothelial carcinoma",
                    "criterion": "prior systemic anticancer treatment for advanced urothelial carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of another malignancy within 3 years before first dose of BT8009 or residual disease from a previously diagnosed malignancy (with some exceptions).",
            "criterions": [
                {
                    "exact_snippets": "History of another malignancy within 3 years before first dose of BT8009",
                    "criterion": "history of another malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "residual disease from a previously diagnosed malignancy",
                    "criterion": "residual disease from previously diagnosed malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Grade ≥2 peripheral neuropathy",
            "criterions": [
                {
                    "exact_snippets": "Grade ≥2 peripheral neuropathy",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active or untreated CNS and/or carcinomatous meningitis",
            "criterions": [
                {
                    "exact_snippets": "Known active or untreated CNS",
                    "criterion": "central nervous system (CNS) disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": [
                                "active",
                                "untreated"
                            ]
                        },
                        {
                            "requirement_type": "awareness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinomatous meningitis",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy ≥12 weeks.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy ≥12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Parts B-8 and B-9: Prior treatment with an ADC containing an MMAE (vedotin) payload.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with an ADC containing an MMAE (vedotin) payload.",
                    "criterion": "prior treatment with an ADC containing an MMAE (vedotin) payload",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cohort B-8: Locally advanced (unresectable) or metastatic, histologically confirmed breast cancer, either TNBC or hormone receptor (HR) positive and HER-2 negative according to ASCO/CAP guidelines and up to 3 prior lines of therapy for advanced (unresectable) or metastatic disease.",
            "criterions": [
                {
                    "exact_snippets": "Locally advanced (unresectable) or metastatic",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "locally advanced (unresectable)",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "histologically confirmed breast cancer",
                    "criterion": "breast cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                },
                {
                    "exact_snippets": "either TNBC or hormone receptor (HR) positive and HER-2 negative according to ASCO/CAP guidelines",
                    "criterion": "breast cancer subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "triple negative breast cancer (TNBC)",
                                "hormone receptor (HR) positive and HER-2 negative according to ASCO/CAP guidelines"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "up to 3 prior lines of therapy for advanced (unresectable) or metastatic disease",
                    "criterion": "prior lines of therapy for advanced or metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of clinically relevant immunodeficiency",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of clinically relevant immunodeficiency",
                    "criterion": "immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical relevance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active systemic infection requiring therapy, or fever within the last 14 days prior to first dose of BT8009.",
            "criterions": [
                {
                    "exact_snippets": "Active systemic infection requiring therapy",
                    "criterion": "systemic infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "fever within the last 14 days prior to first dose of BT8009",
                    "criterion": "fever",
                    "requirements": [
                        {
                            "requirement_type": "presence within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to first dose of BT8009"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cohort B-4: Patients with histologically confirmed non-mucinous epithelial ovarian, fallopian tube, or primary peritoneal cancer that is Stage III or IV according to the International Federation of Gynecology and Obstetrics (FIGO) or tumor, node and metastasis staging criteria that have progressed following prior therapy.",
            "criterions": [
                {
                    "exact_snippets": "histologically confirmed non-mucinous epithelial ovarian, fallopian tube, or primary peritoneal cancer",
                    "criterion": "cancer type",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "non-mucinous epithelial ovarian cancer",
                                "non-mucinous epithelial fallopian tube cancer",
                                "non-mucinous epithelial primary peritoneal cancer"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Stage III or IV according to the International Federation of Gynecology and Obstetrics (FIGO) or tumor, node and metastasis staging criteria",
                    "criterion": "cancer stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "Stage III",
                                "Stage IV"
                            ]
                        },
                        {
                            "requirement_type": "staging system",
                            "expected_value": [
                                "FIGO",
                                "tumor, node and metastasis"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "have progressed following prior therapy",
                    "criterion": "disease progression after prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression after prior therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cohort B-2 and B-3: Histologically documented urothelial carcinoma, not previously treated with enfortumab vedotin (EV). Patients with resectable, locally advanced urothelial carcinoma are ineligible. Must have had progression or recurrence of urothelial cancer during or following receipt of most recent therapy.",
            "criterions": [
                {
                    "exact_snippets": "Histologically documented urothelial carcinoma",
                    "criterion": "urothelial carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "histological documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not previously treated with enfortumab vedotin (EV)",
                    "criterion": "prior treatment with enfortumab vedotin",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with resectable, locally advanced urothelial carcinoma are ineligible",
                    "criterion": "resectable, locally advanced urothelial carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Must have had progression or recurrence of urothelial cancer during or following receipt of most recent therapy",
                    "criterion": "progression or recurrence of urothelial cancer after most recent therapy",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cohort B-1: Histologically documented urothelial carcinoma, previously treated with enfortumab vedotin (EV). Patients with resectable, locally advanced urothelial carcinoma are ineligible. Must have had progression or recurrence of urothelial cancer during or following receipt of most recent therapy.",
            "criterions": [
                {
                    "exact_snippets": "Histologically documented urothelial carcinoma",
                    "criterion": "urothelial carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "histological documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "previously treated with enfortumab vedotin (EV)",
                    "criterion": "enfortumab vedotin (EV) treatment",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with resectable, locally advanced urothelial carcinoma are ineligible",
                    "criterion": "resectable, locally advanced urothelial carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Must have had progression or recurrence of urothelial cancer during or following receipt of most recent therapy",
                    "criterion": "progression or recurrence of urothelial cancer",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "during receipt of most recent therapy",
                                "following receipt of most recent therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Part A-1 cohorts:",
            "criterions": [
                {
                    "exact_snippets": "Part A-1 cohorts",
                    "criterion": "trial cohort assignment",
                    "requirements": [
                        {
                            "requirement_type": "cohort",
                            "expected_value": "Part A-1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have measurable disease per RECIST 1.1.",
            "criterions": [
                {
                    "exact_snippets": "measurable disease per RECIST 1.1.",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment criteria",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with uncontrolled hypertension",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with advanced, histologically confirmed pancreatic, breast, non-small-cell lung cancer (NSCLC), gastric, esophageal, head and neck, or ovarian tumors that recurred after or has been refractory to prior therapy (fresh tumor biopsy or an archived sample testing for Nectin-4 expression).",
            "criterions": [
                {
                    "exact_snippets": "advanced, histologically confirmed pancreatic, breast, non-small-cell lung cancer (NSCLC), gastric, esophageal, head and neck, or ovarian tumors",
                    "criterion": "tumor type and confirmation",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "pancreatic",
                                "breast",
                                "non-small-cell lung cancer (NSCLC)",
                                "gastric",
                                "esophageal",
                                "head and neck",
                                "ovarian"
                            ]
                        },
                        {
                            "requirement_type": "confirmation",
                            "expected_value": "histologically confirmed"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        }
                    ]
                },
                {
                    "exact_snippets": "tumors that recurred after or has been refractory to prior therapy",
                    "criterion": "tumor response to prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "recurrence or refractoriness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "fresh tumor biopsy or an archived sample testing for Nectin-4 expression",
                    "criterion": "tumor sample for Nectin-4 testing",
                    "requirements": [
                        {
                            "requirement_type": "sample availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "sample type",
                            "expected_value": [
                                "fresh tumor biopsy",
                                "archived sample"
                            ]
                        },
                        {
                            "requirement_type": "testing",
                            "expected_value": "Nectin-4 expression"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cohort B-5: Patients with triple-negative breast cancer confirmed negative for estrogen receptor (ER) and progesterone receptor (PR) and negative for human epidermal growth factor receptor 2 (HER2) (i.e., triple-negative) that have progressed following prior therapy.",
            "criterions": [
                {
                    "exact_snippets": "triple-negative breast cancer",
                    "criterion": "breast cancer subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": "triple-negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmed negative for estrogen receptor (ER)",
                    "criterion": "estrogen receptor (ER) status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmed negative for ... progesterone receptor (PR)",
                    "criterion": "progesterone receptor (PR) status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "negative for human epidermal growth factor receptor 2 (HER2)",
                    "criterion": "human epidermal growth factor receptor 2 (HER2) status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "have progressed following prior therapy",
                    "criterion": "disease progression after prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression after prior therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Part D supplementary PK: Patients must have histologically confirmed urothelial (transitional cell) carcinoma (patients with squamous differentiation or mixed cell types are eligible); ovarian; triple-negative breast; or non-small cell lung cancer that have been previously treated with a locally approved therapy.",
            "criterions": [
                {
                    "exact_snippets": "histologically confirmed urothelial (transitional cell) carcinoma (patients with squamous differentiation or mixed cell types are eligible)",
                    "criterion": "urothelial (transitional cell) carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "squamous differentiation or mixed cell types are eligible",
                    "criterion": "squamous differentiation or mixed cell types in urothelial carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ovarian",
                    "criterion": "ovarian cancer",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "triple-negative breast",
                    "criterion": "triple-negative breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "non-small cell lung cancer",
                    "criterion": "non-small cell lung cancer",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "that have been previously treated with a locally approved therapy",
                    "criterion": "prior treatment with locally approved therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cohort B-9: Histologically confirmed advanced/metastatic squamous or non-squamous NSCLC, negative for oncogenic driver mutations (EGFR, KRAS, ALK, BRAF, MET, ERRB2).",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed advanced/metastatic squamous or non-squamous NSCLC",
                    "criterion": "non-small cell lung cancer (NSCLC)",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        },
                        {
                            "requirement_type": "histology subtype",
                            "expected_value": [
                                "squamous",
                                "non-squamous"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "negative for oncogenic driver mutations (EGFR, KRAS, ALK, BRAF, MET, ERRB2)",
                    "criterion": "oncogenic driver mutations (EGFR, KRAS, ALK, BRAF, MET, ERRB2)",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of interstitial lung disease",
            "criterions": [
                {
                    "exact_snippets": "History of interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with advanced, histologically confirmed urothelial (transitional cell) carcinoma that recurred after or has been refractory to prior therapy (fresh tumor biopsy or an archived sample must be submitted); or",
            "criterions": [
                {
                    "exact_snippets": "advanced, histologically confirmed urothelial (transitional cell) carcinoma",
                    "criterion": "urothelial (transitional cell) carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        }
                    ]
                },
                {
                    "exact_snippets": "recurred after or has been refractory to prior therapy",
                    "criterion": "response to prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "recurrence or refractoriness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "fresh tumor biopsy or an archived sample must be submitted",
                    "criterion": "tumor sample submission",
                    "requirements": [
                        {
                            "requirement_type": "submission",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active keratitis or corneal ulcerations",
            "criterions": [
                {
                    "exact_snippets": "Active keratitis",
                    "criterion": "keratitis",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "corneal ulcerations",
                    "criterion": "corneal ulcerations",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must have exhausted all standard treatment options, including appropriate targeted therapies; or patients for which no standard therapy is considered appropriate",
            "criterions": [
                {
                    "exact_snippets": "Must have exhausted all standard treatment options, including appropriate targeted therapies",
                    "criterion": "standard treatment options",
                    "requirements": [
                        {
                            "requirement_type": "exhaustion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients for which no standard therapy is considered appropriate",
                    "criterion": "standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "appropriateness",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Key Exclusion Criteria (all patients):",
            "criterions": []
        },
        {
            "line": "Key Inclusion Criteria",
            "criterions": []
        },
        {
            "line": "* Part A-2:",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}